SUTRO BIOPHARMA, INC. Tax Withholding Paid on Stock Awards
SUTRO BIOPHARMA, INC. (STRO) reported Tax Withholding Paid on Stock Awards of $160.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $160.00K, a 11.11% decline year-over-year.
- SUTRO BIOPHARMA, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $67.00K, a 179.17% increase year-over-year.
- SUTRO BIOPHARMA, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $25.00K, a 66.22% decline year-over-year.
- SUTRO BIOPHARMA, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $332.00K, a 34.77% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $509.00K, a 3.88% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $490.00K, a 5.83% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $463.00K, a 53.09% decline from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $160.00K 10-Q · filed 2026-08-12 | $227.00K derived: sum of 3 quarters · filed 2026-08-12 | $252.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $160.00K 10-Q · filed 2026-05-14 | $227.00K derived: sum of 2 quarters · filed 2026-05-14 | $252.00K derived: sum of 3 quarters · filed 2026-05-14 | $312.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $92.00K derived: sum of 2 quarters · filed 2026-03-23 | $152.00K derived: sum of 3 quarters · filed 2026-08-12 | $332.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $85.00K derived: sum of 2 quarters · filed 2026-08-12 | $265.00K 10-Q · filed 2025-11-06 | $289.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $240.00K 10-Q · filed 2026-08-12 | $264.00K derived: sum of 3 quarters · filed 2026-08-12 | $338.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $180.00K 10-Q · filed 2026-05-14 | $204.00K derived: sum of 2 quarters · filed 2026-05-14 | $278.00K derived: sum of 3 quarters · filed 2026-05-14 | $315.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $98.00K derived: sum of 2 quarters · filed 2026-03-23 | $135.00K derived: sum of 3 quarters · filed 2026-03-23 | $509.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $111.00K derived: sum of 2 quarters · filed 2025-11-06 | $485.00K 10-Q · filed 2025-11-06 | $485.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $411.00K 10-Q · filed 2025-08-07 | $411.00K derived: sum of 3 quarters · filed 2025-08-07 | $444.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $374.00K 10-Q · filed 2025-05-08 | $374.00K derived: sum of 2 quarters · filed 2025-05-08 | $407.00K derived: sum of 3 quarters · filed 2025-05-08 | $413.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $33.00K derived: sum of 2 quarters · filed 2025-03-13 | $39.00K derived: sum of 3 quarters · filed 2025-03-13 | $490.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $39.00K derived: sum of 2 quarters · filed 2024-11-13 | $490.00K 10-Q · filed 2024-11-13 | $490.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $457.00K 10-Q · filed 2024-08-13 | $457.00K derived: sum of 3 quarters · filed 2025-03-13 | $507.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $451.00K 10-Q · filed 2024-05-13 | $451.00K derived: sum of 2 quarters · filed 2025-03-13 | $501.00K derived: sum of 3 quarters · filed 2025-03-13 | $510.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $50.00K derived: sum of 2 quarters · filed 2025-03-13 | $59.00K derived: sum of 3 quarters · filed 2025-03-13 | $463.00K 10-K · filed 2025-03-13 |
| 2022-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $59.00K derived: sum of 2 quarters · filed 2023-11-13 | $463.00K 10-Q · filed 2023-11-13 | $463.00K derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $413.00K 10-Q · filed 2023-08-10 | $413.00K derived: sum of 3 quarters · filed 2024-03-25 | $993.00K derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $404.00K 10-Q · filed 2023-05-15 | $404.00K derived: sum of 2 quarters · filed 2024-03-25 | $984.00K derived: sum of 3 quarters · filed 2024-03-25 | $984.00K derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $580.00K derived: sum of 2 quarters · filed 2024-03-25 | $580.00K derived: sum of 3 quarters · filed 2024-03-25 | $987.00K 10-K · filed 2024-03-25 |
| 2021-09-30 | $580.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $580.00K derived: sum of 2 quarters · filed 2022-11-08 | $987.00K 10-Q · filed 2022-11-08 | $987.00K derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $407.00K 10-Q · filed 2022-08-08 | $407.00K derived: sum of 3 quarters · filed 2023-03-30 | |
| 2021-03-31 | $407.00K 10-Q · filed 2022-05-09 | $407.00K derived: sum of 2 quarters · filed 2023-03-30 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $314.00K 10-K · filed 2023-03-30 | ||
| 2020-09-30 | $314.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $297.00K 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $297.00K 10-Q · filed 2020-11-05 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |